* Surmodics Inc SRDX.OQ SRDX.O is expected to show a
fall in
quarterly revenue when it reports results on April 26.
* The Eden Prairie Minnesota-based company is expected to
report
a 0.9% decrease in revenue to $25.86 million from $26.11 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Surmodics Inc is
for a
loss of 48 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Surmodics
Inc is
$60, above its last closing price of $24.12.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.65 -0.66 -0.50 Beat 23.8
Sep. 30 2022 -0.45 -0.45 -0.26 Beat 42.4
Jun. 30 2022 -0.38 -0.38 -0.34 Beat 11.3
Mar. 31 2022 -0.35 -0.34 -0.22 Beat 35.3
Dec. -0.31 -0.31 -0.13 Beat 58.5
31 2021
Sep. 30 2021 -0.25 -0.25 -0.10 Beat 60
Jun. 30 2021 -0.15 -0.17 -0.17 Met -2
Mar. 31 2021 0.66 0.63 0.62 Missed -2.1
This summary was machine generated April 24 at 18:31 GMT. All
figures in US dollars unless otherwise stated